G01N 2333/525
Tumor necrosis factor [tnf]
Official title: Tumor necrosis factor [TNF]
G01N2333/525 (Tumor necrosis factor [tnf]) appears on 229 US grants and 496 published applications in this corpus.
Search patents in G01N- Granted patents
- 229
- Published applications
- 496
- Assignees
- 299
- Inventors
- 1,023
- Latest grant
- 14 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1998 | 4 | 0 |
| 1999 | 4 | 0 |
| 2000 | 4 | 0 |
| 2001 | 7 | 0 |
| 2002 | 3 | 9 |
| 2003 | 11 | 15 |
| 2004 | 3 | 6 |
| 2005 | 5 | 15 |
| 2006 | 4 | 6 |
| 2007 | 6 | 11 |
| 2008 | 7 | 9 |
| 2009 | 1 | 12 |
| 2010 | 3 | 22 |
| 2011 | 3 | 14 |
| 2012 | 2 | 18 |
| 2013 | 5 | 17 |
| 2014 | 9 | 23 |
| 2015 | 7 | 27 |
| 2016 | 8 | 38 |
| 2017 | 20 | 20 |
| 2018 | 17 | 27 |
| 2019 | 12 | 23 |
| 2020 | 15 | 27 |
| 2021 | 16 | 29 |
| 2022 | 11 | 26 |
| 2023 | 13 | 20 |
| 2024 | 15 | 34 |
| 2025 | 11 | 29 |
| 2026 | 3 | 19 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Methods of treating an autoimmune disease with a human interleukin-3 (IL-3)-diphtheria toxin conjugate (DT-IL3)14 Jul 2026US 12,678,485 B2Stemline Therapeautics, Inc.
- Methods of detecting and treating cerebral aneurysms17 Feb 2026US 12,553,904 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- Method of monitoring anti-TNF therapy in a subject suffering from rheumatoid arthritis based in part on a trained machine learning classifier13 Jan 2026US 12,525,318 B2Scipher Medicine Corporation
- Complexes between CD40 and compounds comprising benzimidazole moieties18 Nov 2025US 12,474,348 B2Ucb Biopharma Srl
- Biomarker panels for on-treatment prediction of response to immuno-oncology drugs30 Sep 2025US 12,429,485 B2The Brigham and Women S Hospital, Inc.
- Methods for detecting an anti-drug antibody (ada) against an anti-tnf alpha antibody1 Oct 2026US 2026/0298940 A1
- Methods of treating alzheimer's disease17 Sep 2026US 2026/0274931 A1Klaritos, Inc.
- Humoral Immune Activators for the Treatment of Humoral Immunosuppressed Pathologies, Cancer and Infectious Disease and Humoral Immune Suppressors for the Treatment of Inflammatory Diseases3 Sep 2026US 2026/0256811 A1Navrogen, Inc.
- Analyte quantification with bead and immuno qpcr-based elisa (biq-elisa)3 Sep 2026US 2026/0258475 A1
- Methods for detecting or treating atherosclerosis27 Aug 2026US 2026/0250372 A9City University of Hong Kong
Most cited
By later US patents
- Methods and apparatus for conducting multiple measurements on a sample125US 7,858,321 B2Meso Scale Technologies, LLC. · 2010
- Prostaglandin E2 dual variable domain immunoglobulins and uses thereof85US 8,822,645 B2AbbVie Inc. · 2014
- Tumor necrosis factor delta polypeptides81US 6,541,224 B2Human Genome Sciences, Inc. · 2003
- Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists69US 7,238,715 B2The Feinstein Institute for Medical Research · 2007
- Dual variable domain immunoglobulins and uses thereof65US 8,735,546 B2AbbVie Inc. · 2014